Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer

Therapeutic Advances in Urology

Volumn 5, Issue 4, 2013, Pages 201-210

  Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

AFFIRM trial; enzalutamide; metastatic castrate resistant prostate cancer; PREVAIL trial

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; LIVER FUNCTION; METASTATIC CASTRATE RESISTANT PROSTATE CANCER; MUSCULOSKELETAL PAIN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT;

EID: 84880904867     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213490054     Document Type: Review

References (18)

1. Berthold D. Pond G. Soban F. De Wit R. Eisenberger M. Tannock I. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26: 242–245.
2. British Association of Urological Surgeons (2009) BAUS Cancer Registry: Analyses of Minimum Data Set for Urological Cancers January 1st–31st December 2008. London: BAUS.
3. de Bono J. Logothetis C. Molina A. Fizazi K. North S. Chu L. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005.
4. de Bono J. Oudard S. Ozguroglu M. Hansen S. Machiels J. Kocak I. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154.
5. Dorff T. Crawford E. (2013) Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 24: 31–38.
6. Fizazi K. Scher H. Molina A. Logothetis C. Chi K. Jones R. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13: 983–992.
7. Kantoff P. Higano C. Shore N. Berger E. Small E. Penson D. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.
8. Mohler J. (2008) Castration–recurrent prostate cancer is not androgen independent. Adv Exp Med Biol 617: 223–234.
9. O–Donnell A. Judson I. Dowsett M. Raynaud F. Dearnaley D. Mason M. (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90: 2317–2325.
10. Parker C. Heinrich D. O–Sullivan J. Fossä S. Chodacki A. Demkow T. (2011) Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Oral presentation. Program and abstracts of the 2011 European Multidisciplinary Cancer Congress, 23–27 September 2011, Stockholm, Sweden. Abstract LBA 1.
11. Rathkopf D. Smith M. De Bono J. Logothetis C. Shore N. De Souza P. (2013) Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. J Clin Oncol 31(Suppl. 6): abstract 5.
12. Ryan C. Smith M. de Bono J. Molina A. Logothetis C. de Souza P. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138–148.
13. Scher H. Beer T. Higano C. Anand A. Taplin M. Efstathiou E. (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437–1446.
14. Scher H. Fizazi K. Saad F. Taplin M. Sternberg C. Miller K. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197.
15. Sternberg C. De Bono J. Chi K. Fizazi K. Mulders P. Hirmand M. (2013) Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. J Clin Oncol 31(Suppl. 6): abstract 16.
16. Tannock I. de Wit R. Berry W. Horti J. Pluzanska A. Chi K. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.
17. Tran C. Ouk S. Clegg N. Chen Y. Watson P. Arora V. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787–790.
18. Yuan X. Balk S. (2009) Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27: 36–41.